Role of Container Type in Stability Testing

During ICH stability studies, the container becomes the product’s primary defense against environmental stressors such as heat, humidity, light, and oxygen. Regulatory guidelines require that stability data be generated using the actual market-intended container closure system (CCS). Thus, choosing the wrong container can invalidate the stability results altogether.

Refer to ICH guidelines for container-specific stability recommendations.

Common Container Types in Pharmaceutical Packaging

Let’s look at the common container types and their respective pros and cons in the context of stability:

• Glass Vials (Type I): Highly inert and impermeable, ideal for injectables and sensitive APIs.
• Plastic Bottles (HDPE, PET): Common for oral liquids and solids, but more permeable to moisture and gases.
• Blister Packs (PVC, PVDC, Aclar): Great for unit-dose formats, require evaluation for delamination and seal integrity.
• Ampoules: Hermetically sealed glass, excellent for light and oxygen-sensitive solutions.
• Sachets and Pouches: Used for powders and granules, but prone to puncture and moisture ingress.

Key Factors Affected by Container Type

The choice of container influences several critical stability outcomes:

1. Assay and Degradation: Some plastic containers can adsorb or leach chemicals, altering API levels.
2. Moisture Uptake: Non-glass containers may allow water ingress, accelerating hydrolysis.
3. Oxygen Permeation: HDPE bottles and some blister films may not provide adequate oxygen barriers.
4. Light Protection: Amber glass offers better protection than transparent polymers.
5. Migration of Additives: Plasticizers and stabilizers may migrate into the drug product.

These effects must be simulated in forced degradation and long-term studies to assess real-world performance.

Comparative Study Example: Glass vs Plastic for Oral Solutions

In a comparative study of a vitamin C oral solution, batches stored in Type I glass showed less than 1% assay loss at 3 months under 40°C/75% RH. Meanwhile, the same solution in PET bottles degraded by nearly 5%, attributed to oxygen ingress through the polymer. This illustrates how material permeability influences stability—even when both containers meet pharmacopeial standards.

Checklist for Evaluating Container Type During Development

• Chemical compatibility with formulation (avoid reactivity)
• Water vapor transmission rate (WVTR)
• Oxygen transmission rate (OTR)
• Resistance to light, breakage, and stress
• Closure system compatibility and sealing integrity
• Suitability for sterilization (if required)
• Global regulatory acceptability

These parameters should be evaluated under simulated transport and storage conditions before final selection.

Regulatory Expectations for Container Selection

Regulators like the USFDA and EMA mandate that stability data must reflect the final market presentation. If a different container is used during R&D, bridging studies or justifications are required in the dossier.

• Include extractables and leachables studies (USP , )
• Document justification for container choice
• Provide validation reports for sealing and integrity

These records should appear in CTD Module 3.2.P.7 of the regulatory submission.

How to Conduct Compatibility Testing Based on Container Type

Container compatibility must be tested throughout the product lifecycle. Key test methods include:

• Assay and impurity profile trending over time
• Leachables identification using LC-MS, GC-MS, ICP-MS
• Stress testing at ICH conditions (30°C/65% RH, 40°C/75% RH)
• Photostability testing per ICH Q1B
• Container Closure Integrity Testing (CCI) for sterile products

These studies must use samples stored in the exact packaging system proposed for commercial use.

Case Study: Impact of Closure Incompatibility with Plastic Vials

A company conducted a stability study for a pediatric oral antibiotic in plastic vials with screw caps. After three months at 30°C/75% RH, drug loss and microbial contamination were observed. Investigation revealed incomplete sealing due to torque loss under heat expansion. Switching to an induction-sealed cap resolved the issue and ensured container closure integrity (CCI).

This reinforces the need to validate closures in conjunction with container material and product formulation.

Tips for Selecting the Right Container Type Based on Product Class

• Injectables: Type I glass vial or ampoule + rubber stopper + aluminum seal
• Oral liquids: Amber glass or PET bottle + child-resistant cap
• Solid dose forms: PVC/PVDC blister or HDPE bottle with desiccant
• Topicals: Laminate tubes or high-barrier plastic jars
• Inhalers: Aluminum canister with metered dose valve

Always assess container impact on dosage delivery, not just physical stability.

Internal Documentation Requirements for Container Type Evaluation

Ensure the following documents are included in your packaging development file:

• Material specifications and vendor CoAs
• Summary of compatibility studies
• CCI validation reports
• Visual inspection protocols and sealing SOPs
• Photostability and migration test reports
• Packaging description in the stability protocol

Refer to Pharma SOPs for templates to document packaging qualification steps.

Link Between Container Selection and Product Shelf Life

Suboptimal containers can shorten shelf life by accelerating degradation. For instance, polyethylene containers with high moisture permeability may reduce a hygroscopic API’s shelf life from 24 to 12 months. On the contrary, blister packs with Aclar films or glass containers can extend shelf life by reducing environmental exposure.

Hence, container choice is a shelf-life defining factor—not just a packaging decision.

Conclusion

The container type used in pharmaceutical stability testing can make or break a product’s success. By evaluating chemical compatibility, moisture/oxygen permeability, mechanical protection, and regulatory compliance, pharma professionals can select the right packaging solution that ensures product integrity throughout the shelf life. Always integrate container evaluation into the early stages of formulation development and document findings rigorously.

References:

• ICH Q1A(R2) Stability Testing of New Drug Substances and Products
• ICH Q1B Photostability Testing of New Drug Substances and Products
• USP : Containers – Plastics
• USP : Assessment of Extractables
• FDA Guidance for Industry – Container Closure Systems
• EMA Guideline on Plastic Immediate Packaging Materials

Choosing the Right Packaging to Safeguard Pharmaceutical Products Against Photodegradation

Protecting pharmaceutical products from the harmful effects of light exposure is an essential consideration in drug development. Photodegradation can lead to potency loss, impurity formation, and color changes—compromising product quality, safety, and regulatory compliance. The container-closure system serves as the first line of defense against photolytic damage. Therefore, selecting a suitable container for photostability protection is a critical step guided by scientific, regulatory, and material-specific criteria. This tutorial outlines best practices for evaluating and selecting packaging systems to meet the light protection needs of drug products, in accordance with ICH Q1B and global standards.

1. Importance of Container Selection in Photostability

Why Packaging Matters:

• Light exposure can initiate photochemical reactions that degrade APIs or excipients
• The wrong container may transmit harmful wavelengths, accelerating degradation
• Regulatory approval may be denied or delayed without validated packaging protection

ICH Q1B Guidance:

• Photostability studies must include testing in the final or proposed market container
• Results help determine labeling needs (e.g., “Protect from light”) and storage conditions
• Both drug substance and product containers must be evaluated when applicable

2. Types of Containers Used for Photostability Protection

Common Primary Containers:

• Glass Vials and Bottles: Amber, clear, or flint glass with varying light transmittance
• Plastic Containers: Polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polyethylene terephthalate (PET), often with additives or colorants
• Blister Packs: PVC, PVDC, Aclar®, and aluminum-based films for oral dosage forms
• Syringes and Cartridges: Made from glass or plastic; require validation of light barrier properties

Secondary Packaging Considerations:

• Outer cartons, inserts, and foil overwraps add a second level of protection
• Regulatory bodies may accept light protection achieved via secondary packaging only if validated

3. Mechanisms of Light Protection by Packaging

1. UV Absorption:

• Amber glass and UV-stabilized plastics absorb light in the 200–450 nm range
• Protects against photodegradation caused by UVB and UVA light

2. Light Scattering and Reflection:

• Opaque containers scatter or reflect incident light, reducing internal transmission
• Useful for formulations sensitive to visible light (>450 nm)

3. Pigment-Based Shielding:

• Incorporating titanium dioxide or iron oxide pigments blocks light penetration in plastic containers
• Colorants must be biocompatible and non-leachable

4. Evaluating Light Transmission Through Packaging

Spectral Transmission Testing:

• Use UV-Vis spectrophotometer to measure light transmittance through container walls
• Focus on 290–700 nm range, with particular attention to 320–400 nm (UV-A) and 400–500 nm (visible)
• Amber glass typically transmits 80%

Labeling Thresholds Based on Transmittance:

• Low transmission (<10%): May not require “Protect from light” label if supported by stability data
• Moderate transmission (10–50%): Likely to require protective labeling and/or secondary packaging
• High transmission (>50%): Not suitable for light-sensitive products without additional protection

Testing Under ICH Q1B Conditions:

• Expose product in final container to 1.2 million lux hours and 200 Wh/m² UV
• Compare product degradation in transparent vs. opaque or amber containers
• Evaluate visual and chemical changes (e.g., assay, impurities, color shift)

5. Packaging Material Comparison: Strengths and Limitations

6. Packaging Design Considerations for Light-Sensitive Drugs

Form-Factor-Based Selection:

• Injectables: Amber vials or prefilled syringes with UV filters
• Oral solutions: Opaque or amber PET bottles with light-resistant labels
• Solid dosage: Aluminum-aluminum blisters or foil-pouched bottles

Additional Protective Measures:

• Light-blocking sleeves for infusion bags or IV tubing
• Colored shrink wraps or over-labels to block specific wavelengths
• Carton designs with UV-filter coatings or reflective layers

7. Regulatory Expectations and Documentation

Documentation in Submission Dossiers:

• Module 3.2.P.2: Packaging selection justification based on stability data
• Module 3.2.P.7: Description of container-closure materials and configurations
• Module 3.2.P.8.3: Photostability test results under ICH Q1B conditions

Regulatory Review Trends:

• FDA and EMA may request additional studies if container is not inherently light-protective
• WHO PQ prefers performance-based validation over theoretical packaging claims
• Post-approval changes to container require bridging data and new validation

8. Case Study: Choosing Packaging for a Light-Sensitive Oral Solution

Background:

Multivitamin oral liquid with riboflavin and folic acid—both known to degrade under light exposure.

Options Evaluated:

• Clear PET bottle + foil overwrap
• Amber PET bottle without carton
• Opaque HDPE bottle with carton

Findings:

• Clear PET showed >20% potency loss after ICH Q1B exposure
• Amber PET contained degradation to <5%, but label faded under visible light
• Opaque HDPE + carton showed <1% loss and excellent color retention

Final Decision:

• Selected opaque HDPE bottle with protective carton
• Added “Protect from light. Store in original package” to labeling
• Results documented in Module 3.2.P.8.3 and packaging strategy justified in 3.2.P.2

9. SOPs and Validation Tools

Available from Pharma SOP:

• Photostability Container Evaluation SOP
• Light Transmission Testing Protocol Template
• Packaging Qualification Form for Photostability Claims
• Container Risk Assessment Tool (ICH Q1B Aligned)

For more implementation resources, visit Stability Studies.

Conclusion

Container selection is a pivotal component of photostability management in pharmaceutical development. By understanding light transmission properties, evaluating degradation risks, and validating container performance under ICH Q1B exposure conditions, formulators can ensure product quality, regulatory acceptance, and patient safety. Whether choosing amber glass, pigmented polymers, or multilayer blisters, the packaging must be science-driven, risk-informed, and thoroughly documented to support long-term product success.